Primary biliary cirrhosis is a chronic cholestatic liver disease of adults. This disorder is
characterised histologically by chronic non-suppurative destruction of interlobular bile ducts …

Background Ursodeoxycholic acid is administered to patients with primary biliary cirrhosis, a
chronic progressive inflammatory autoimmune‐mediated liver disease with unknown …

The biochemical response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis is a
strong predictor of long‐term outcome and thus facilitates the rapid identification of patients …

OBJECTIVES The effect of ursodeoxycholic acid (UDCA) treatment on survival and liver
histological progression of primary biliary cirrhosis (PBC) remains uncertain. The aim of this …

OBJECTIVES Ursodeoxycholic acid (UDCA) is used for primary biliary cirrhosis (PBC), but
the beneficial effects remain controversial. METHODS We performed an updated systematic …

Background Primary biliary cholangitis (previously primary biliary cirrhosis) is a chronic liver
disease caused by the destruction of small intra‐hepatic bile ducts resulting in stasis of bile …

6-ethyl-chedeoxycholic acid (6E-CDCA) is a farnesoid X receptor (FXR) ligand endowed
with agonistic activity under development for treatment of cholestatic liver diseases including …

PBC is a relatively rare but important cause of chronic cholestatic liver disease that affects
predominantly middle-aged women. 1 Elevations in serum alkaline phosphatase (ALP) …

BACKGROUND & AIMS: Portal hypertension can complicate primary biliary cirrhosis, but
studies evaluating the direct measurement of the portohepatic gradient (PHG) are rare. The …

THE JAPANESE VERSION of the clinical practice guidelines for primary biliary cirrhosis
(PBC) was developed in 2012 by the Intractable Hepatobiliary Disease Study Group, with …